We aimed to assess the potency of a screening-strategy utilizing repeatedly measured NT-proBNP levels to detect trastuzumab-induced cardiotoxicity measured with three-dimensional echocardiography (3DE) in a representative cohort of HER2-positive breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.